This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Alamar Biosciences launches NULISA DBS Kit
Tech product launch

Alamar Biosciences launches NULISA DBS Kit

Analysis based on 7 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026

Sentiment
60
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch of the NULISA DBS Extraction Kit by Alamar Biosciences is expected to positively impact the company's stock price due to expanded market reach and potential for increased sales in the proteomics sector. This innovation could also benefit companies like Capitainer, Telimmune, C-Mitra, and Torquato Tasso, whose microsampling devices are compatible with the new kit, by increasing demand for their products.

Biotechnology Healthcare
Event Summary

Alamar Biosciences launched its NULISA DBS Extraction Kit on June 2, 2026, which allows researchers to use home-collected fingerstick samples for ultra-high sensitivity, multiplex proteomics. This new kit enables longitudinal and decentralized translational study designs in neurology, inflammation, and population health, which were previously challenging with traditional venous blood draws. The NULISA DBS Extraction Kit standardizes protein extraction across various third-party microsampling devices, including those from Capitainer, Telimmune, C-Mitra, and Torquato Tasso, making proteomics more accessible for population-based screening programs. Dr. Yuling Luo, CEO of Alamar Biosciences, emphasized the kit's role in unlocking high-quality proteomic data from remotely collected samples, while Dr. Amanda Heslegrave from UCL highlighted its transformative capability for population studies.

Entities Involved
priv
Alamar Biosciences
Alamar Biosciences launched its NULISA DBS Extraction Kit, which is expected to expand the accessibility and application of its proteomics technology, potentially increasing its market share and revenue.
Importance 100.0 Sentiment 70.0
per
Yuling Luo
As the founder, CEO, and chair of Alamar Biosciences, Yuling Luo announced the launch of the NULISA DBS Extraction Kit, highlighting the company's commitment to making proteomics more accessible.
Importance 70.0 Sentiment 60.0
per
Amanda Heslegrave
As co-lead of Biomarker Factory at UCL, UK DRI, Amanda Heslegrave provided an endorsement for the NULISA DBS Extraction Kit, emphasizing its transformative capability for population studies and longitudinal research.
Importance 40.0 Sentiment 50.0
oth
Capitainer
Capitainer is one of the third-party microsampling device providers whose products are compatible with the NULISA DBS Extraction Kit, potentially increasing its product usage.
Importance 20.0 Sentiment 10.0
priv
Telimmune
Telimmune is one of the third-party microsampling device providers whose products are compatible with the NULISA DBS Extraction Kit, potentially increasing its product usage.
Importance 20.0 Sentiment 10.0
oth
Torquato Tasso
Torquato Tasso is one of the third-party microsampling device providers whose products are compatible with the NULISA DBS Extraction Kit, potentially increasing its product usage.
Importance 20.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.